These differed somewhat from the full study population in the distribution of risk (relatively higher share with CPS-EG score ≥3 in PAL+ET arm, lower with Ki-67 ≤15%), breast cancer treatments at baseline (fewer mastectomies, fewer started ET before PAL or ET with tamoxifen, fewer on goserelin, and fewer hysterectomies), and other illnesses (one illness less chronic or ongoing). Here, MKI67 is linked to breast carcinoma.